Online citations, reference lists, and bibliographies.

Analysis Of Topical Cyclosporine Treatment Of Patients With Dry Eye Syndrome: Effect On Conjunctival Lymphocytes.

K. S. Kunert, A. Tisdale, M. Stern, J. Smith, I. Gipson
Published 2000 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
OBJECTIVE To study the effect of topical cyclosporine on lymphocyte activation within the conjunctiva of patients with moderate to severe dry eye syndrome (Sjögren and non-Sjögren). METHODS Biopsy specimens were obtained at baseline and after 6 months of cyclosporine treatment from eyes of 32 patients with moderate to severe dry eye syndrome; 19 were cyclosporine treated (0.05% cyclosporine, n = 13; 0.1% cyclosporine, n = 6) and 13 were vehicle treated. Within this group there were 12 with Sjögren syndrome and 20 with non-Sjögren syndrome. Biopsy tissue was analyzed using immunohistochemical localization of binding of monoclonal antibodies to lymphocytic markers CD3, CD4, and CD8 as well as lymphocyte activation markers CD11a and HLA-DR. RESULTS In cyclosporine-treated eyes, biopsy results of conjunctivae showed decreases in the number of cells positive for CD3, CD4, and CD8, while in vehicle-treated eyes, results showed increases in these markers, although these differences were not statistically significant. Following treatment with 0.05% cyclosporine, there was a significant decrease in the number of cells expressing the lymphocyte activation markers CD11a (P<.05) and HLA-DR (P<.05), indicating less activation of lymphocytes as compared with vehicle treatment. Within the Sjögren patient subgroup, those treated with 0.05% cyclosporine also showed a significant decrease in the number of cells positive for CD11a (P<.001) as well as CD3 (P<.03), indicating a reduction in number of activated lymphocytes. CONCLUSION Treatment of dry eye syndrome with topical cyclosporine significantly reduced the numbers of activated lymphocytes within the conjunctiva. Arch Ophthalmol. 2000;118:1489-1496
This paper references
Flow cytometry in impression cytology specimens. A new method for evaluation of conjunctival inflammation.
C. Baudouin (1997)
10.1001/archopht.1989.01070020276038
Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops.
R. Kaswan (1989)
10.1097/00003226-199311000-00004
Immunological Analysis and Treatment of Mooren's Ulcer with Cyclosporin A Applied Topically
J. Zhao (1993)
10.1001/archopht.1993.01090010023009
Lymphocytic infiltration of the conjunctiva and the salivary gland in Sjögren's syndrome.
T. Hikichi (1993)
Intraoperative use of mitomycin C and postoperative use of topical cyclosporine A in the treatment of tarsal vernal keratoconjunctivitis
AG Secchi (1997)
Conjunctival cytologic features of primary Sjögren's syndrome.
S. Pflugfelder (1990)
junctival biopsy in Sjögren ’ s syndrome : correlations between histological and immunohistochemical features
M Raphael (1988)
10.1136/bjo.68.9.674
Senile atrophy of the human lacrimal gland: the contribution of chronic inflammatory disease.
B. Damato (1984)
10.1159/000027387
Conjunctival Epithelium Expression of HLA-DR in Dry Eye Patients
K. Tsubota (1998)
10.1016/S0161-6420(99)00176-1
Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease1
K. Sall (2000)
10.1007/978-1-4615-5359-5_143
Conjunctival impression cytology from dogs with keratoconjunctivitis sicca. Pre- and post-treatment with topical cyclosporine.
D. Bounous (1998)
Diagnosis and management of dry eye and ocular surface disorders
AJ Lubniewski (1990)
10.1016/S0733-8635(18)30052-4
Cyclosporine: what clinicians need to know.
J. Koo (1995)
10.1097/00003226-199311000-00008
Effect of Topical Cyclosporin A on Conjunctival T Cells in Patients with Secondary Sjögren’s Syndrome
W. Power (1993)
Sjögren's syndrome: cytokine and Epstein-Barr viral gene expression within the conjunctival epithelium.
D. Jones (1994)
10.1111/j.1365-2559.1988.tb02024.x
Conjunctival biopsy in Sjögren's syndrome: correlations between histological and immunohistochemical features
M. Raphael (1988)
10.1007/978-1-4615-5359-5_142
Preclinical safety studies of cyclosporine ophthalmic emulsion.
O. Angelov (1998)
10.1016/S1054-3589(08)60276-8
In vivo pharmacological effects of ciclosporin and some analogues.
J. Borel (1996)
10.1159/000268003
Flow cytometric analysis of surface antigens on human conjunctival epithelial cells.
T. Fujihara (1997)
10.1016/S0161-6420(90)32478-8
Conjunctival Cytologiec Features of Primary Sjögren's Syndrome
S. Pflugfelder (1990)
10.1046/j.1365-2133.1997.6081584.x
Cyclosporin inhibits intercellular adhesion molecule‐1 expression and reduces mast cell numbers in the asebia mouse model of chronic skin inflammation
A. Oran (1997)
10.1002/art.1780360309
Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community.
C. Vitali (1993)
10.1159/000268041
Topical cyclosporin as an adjunct to topical acyclovir treatment in herpetic stromal keratitis.
K. Gündüz (1997)
10.1016/0092-8674(94)90335-2
Signals and signs for lymphocyte responses
C. Janeway (1994)
Ocular disorders associated with systemic diseases
Sanders (1986)
junctival cytologic features of primary Sjögren ’ s syndrome
SC Pflugfelder (1990)
10.1097/00003226-199307000-00007
Pilot Trial of Cyclosporine 1% Ophthalmic Ointment in the Treatment of Keratoconjunctivitis Sicca
R. Laibovitz (1993)
10.1016/S0002-9394(14)73872-3
Local therapy of corneal allograft rejection with cyclosporine.
J. Zhao (1995)
10.1136/bjo.57.11.852
Histology of the lacrimal gland in keratoconjunctivitis sicca.
J. Williamson (1973)
Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs.
D. Olivero (1991)
10.1111/j.1755-3768.1994.tb02792.x
Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren's syndrome
K. Gündüz (1994)
10.1097/00003226-199811000-00002
The pathology of dry eye: the interaction between the ocular surface and lacrimal glands.
M. Stern (1998)
10.1172/JCI118629
Common T cell receptor clonotype in lacrimal glands and labial salivary glands from patients with Sjögren's syndrome.
I. Matsumoto (1996)
Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
K. Sall (2000)
10.1016/S0161-6420(90)32372-2
Mononuclear cell phenotypes and immunoglobulin gene rearrangements in lacrimal gland biopsies from patients with Sjögren's syndrome.
J. Pepose (1990)
10.1083/jcb.107.1.321
Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells
M. L. Dustin (1988)
10.1007/978-1-4615-5359-5_91
A unified theory of the role of the ocular surface in dry eye.
M. Stern (1998)
10.1016/S0022-1759(97)00207-X
Expression of a soluble form of LFA-1 and demonstration of its binding activity with ICAM-1.
Y. Tominaga (1998)
10.1001/ARCHOPHT.118.5.615
Reliability and validity of the Ocular Surface Disease Index.
R. Schiffman (2000)
10.1001/archopht.1992.01080130123040
Distribution of lymphocytes and cell adhesion molecules in iris biopsy specimens from patients with uveitis.
D. Wakefield (1992)
The immunomodulatory effect of topical cyclosporin A in atopic keratoconjunctivitis.
M. Hingorani (1999)



This paper is referenced by
10.1016/s1542-0124(12)70084-8
Design and conduct of clinical trials: report of the Clinical Trials Subcommittee of the International Dry Eye WorkShop (2007).
K. Tsubota (2007)
10.1002/9780470571224.PSE373
Oil‐in‐Water Nanosized Emulsions: Medical Applications
Shunmugaperumal Tamilvanan (2010)
10.3109/08820538.2015.1114841
Chronic Ocular Complications of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: The Role of Systemic Immunomodulatory Therapy
V. S. Chang (2016)
Cornea Tear Interferon-Gamma as a Biomarker for Evaporative Dry Eye Disease
D. Jackson (2016)
10.1186/s40662-019-0137-2
Dry eye disease immune responses and topical therapy
Charles W. McMonnies (2019)
10.1038/s41419-020-2489-x
FUT1 deficiency elicits immune dysregulation and corneal opacity in steady state and under stress
Kyoung Woo Kim (2020)
How do Functional Tear Tests and Corneal and Anterior Chamber Parameters Change After Topical Cyclosporine -A 0.05% Treatment in Dry Eye Diagnosed Women?
Esra Şahlı (2020)
10.1201/B14144-10
Pathological Effects of Lacrimal Keratoconjunctivitis on the Ocular Surface
S. Yeh (2004)
10.1007/s12325-008-0056-4
The presence of T-lymphocyte subpopulations (CD4 and CD8) in pterygia: Evaluation of the inflammatory response
Richard M. Awdeh (2008)
10.1080/09286580802521309
United States Cost-Effectiveness Study of Two Dry Eye Ophthalmic Lubricants
John Wlodarczyk (2009)
Tear component interference in bead-based biomarker assays using magnetic beads
Larezia Williams (2011)
10.1007/978-3-319-31169-2_5
Sjögren’s Syndrome
Jozef Rovenský (2015)
10.1089/jop.2016.0105
LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease
S. Pflugfelder (2017)
10.1007/s40674-018-0084-4
Ocular Involvement in Sjögren’s Syndrome: Advances in Therapy
John A Gonzales (2018)
10.1080/2331205X.2016.1243771
A review of the ocular manifestations of rheumatoid arthritis
Neerav Lamba (2016)
Ophthalmic Microemulsion: A Comprehensive Review
Kale Mohan (2012)
10.1097/ICO.0b013e31802dffc7
Agreement of Physician Treatment Practices With the International Task Force Guidelines for Diagnosis and Treatment of Dry Eye Disease
S. Wilson (2007)
10.1111/j.1463-5224.2009.00699.x
Conjunctival effects of canine distemper virus-induced keratoconjunctivitis sicca.
Denize E de Almeida (2009)
Rôle pro-inflammatoire des cellules épithéliales de la conjonctive dans un modèle in vitro de sécheresse oculaire
E. Warcoin (2016)
10.1001/ARCHOPHT.124.5.710
Chemokine receptor CCR5 expression in conjunctival epithelium of patients with dry eye syndrome.
A. Gulati (2006)
10.1097/01.ico.0000240079.24583.a1
Comparison of Topical Dry Eye Medications for the Treatment of Keratoconjunctivitis Sicca in a Botulinum Toxin B-Induced Mouse Model
K. Lekhanont (2007)
10.1016/B978-012370585-3.50008-X
New Therapies for Dry Eye Disease
G. Foulks (2008)
10.1016/j.exer.2015.06.032
FTY720 ameliorates Dry Eye Disease in NOD mice: Involvement of leukocytes inhibition and goblet cells regeneration in ocular surface tissue.
Weibao Xiao (2015)
10.1167/IOVS.04-1394
Systemic omega-6 essential fatty acid treatment and pge1 tear content in Sjögren's syndrome patients.
P. Aragona (2005)
Cornea Correlation Between the Inflammatory Marker HLA-DR and Signs and Symptoms in Moderate to Severe Dry Eye Disease
F. Brignole-Baudouin (2017)
10.1155/2019/5491626
Oral Hyaluronic Acid Supplementation for the Treatment of Dry Eye Disease: A Pilot Study
Ye-seul Kim (2019)
10.1038/s41598-018-28861-5
RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model
Chae Eun Kim (2018)
10.2147/IMCRJ.S29960
Topical cyclosporin as an alternative treatment for vision threatening blepharokeratoconjunctivitis: a case report
A. Ismail (2012)
REVISTA BRASILEIRA DE REUMATOLOGIA
Lívia Lovato (2014)
10.1038/mi.2013.20
Chronic Dry Eye Disease is Principally Mediated by Effector Memory Th17 Cells
Y. Chen (2014)
10.1586/1744666X.3.2.195
New approaches in Sjögren’s syndrome therapy
M. Ramos-Casals (2007)
Dry Eye: an Inflammatory Ocular Disease
Michelle Hessen (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar